Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Posts Q1 Profit

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Accelr8 Technology today reported an upswing in revenues and a profit for its first quarter ended Oct. 31.

The Denver-based firm brought in total revenues of $466,362 for the quarter compared to $15,549 for the first quarter of the previous year. Its revenues were boosted by a $244,479 grant from the Internal Revenues Service under the Qualified Therapeutic Discovery program. It also received technical development fees of $210,000, with no such fees received the year before.

Accelr8 disclosed in a recent US Securities and Exchange Commission filing that Novartis Vaccines and Diagnostics is evaluating the firm's BACcel system for identifying the type and quantity of bacterial pathogens in clinical specimens. It noted that Novartis will pay it an undisclosed fee for the evaluation.

Accelr8 posted a profit of $67,250, or $.01 per share, compared to a net loss of $411,981, or $.04 per share, for last year's Q1.

Its R&D spending declined to $111,050 from $160,899, while its SG&A spending increased to $241,560 from 212,683.

The firm finished the quarter with $222,494 in cash and cash equivalents.

"[W]e’re entering a development phase that leads directly to product development for international launch" of the BACcel system, Accelr8 President David Howson said in a statement. "The first system will include critical tests for pathogen targets that represent the greatest threats to ICU patients who become infected."

In Thursday afternoon trade on the American Stock Exchange, shares of Accelr8 were down 3 percent at $1.02.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.